Conference call to discuss the results from the first 3-patient cohort of the Phase I/IIa gene transfer clinical trial using MYO-101 to treat patients with Limb-Girdle Muscular Dystrophy Type 2E (beta-sarcoglycanopathy) will be held on February 27 at 8 am.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.